GoodRx (NASDAQ:GDRX – Free Report) had its price objective increased by Royal Bank of Canada from $5.00 to $7.00 in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a sector perform rating on the stock. Other equities analysts also recently issued research reports about the stock. Truist Financial increased their […]
GoodRx (NASDAQ:GDRX – Get Free Report) had its target price increased by equities research analysts at Truist Financial from $5.50 to $7.50 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 11.61% from the stock’s […]